Breaking Barriers: Safely Targeting Obstructive Hypertrophic Cardiomyopathy at the Source : Episode 1
Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause
Anjali Tiku Owens, MD, examines the unmet needs in treating obstructive hypertrophic cardiomyopathy (oHCM) and explores how novel Cardiac Myosin inhibitors (CMIs) address the root cause of the condition.
Now Viewing
EP: 1.Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause
EP: 2.Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment
EP: 3.Aligning With 2023 ESC Guidelines in oHCM Treatment
EP: 4.Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes
EP: 5.Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice
- The treatment of obstructive hypertrophic cardiomyopathy (oHCM) has a high level of unmet needs, can you discuss these with us?
- How do novel cardiac myosin inhibitors (CMIs) target the underlying cause of oHCM?
2. What has the impact of CMI’s been on the management of oHCM?
- Complements (first line) standard of care
- Addresses the root cause of oHCM
- Narrowing the substantial gap between effective medical therapy and the more definitive invasive treatments like alcohol septal ablation and surgical myectomy.
Related Videos
Related Content
